本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Immix Biopharma, Inc

2.92
-0.0300-1.02%
盤前2.960.0400+1.37%05:03 EDT
成交量:34.86萬
成交額:104.81萬
市值:8,132.88萬
市盈率:-4.17
高:3.12
開:2.95
低:2.91
收:2.95
資料載入中...
2022/05/27

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2022/05/13

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/03/28

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/03/02

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/09

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/01/25

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/01/19

重要事件披露

8-K - Current report
2022/01/12

重要事件披露

8-K - Current report
2022/01/03

重要事件披露

8-K - Current report
2021/12/28

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/12/20

重要事件披露

8-K - Current report
2021/12/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/01

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/11/04

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/28

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/15

SEC問詢函

CORRESP [Cover] - Correspondence
2021/10/15

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/06

SEC問詢函

CORRESP [Cover] - Correspondence